Analyzing skin cells and immune response in systemic sclerosis
Analysis of Dermal Fibroblasts and Immune Cells During Systemic Sclerosis
This study looks at skin and blood samples from people with systemic sclerosis to see how different skin cells and immune cells interact, which could help us understand the disease better and find new treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Lille Academic / other |
| Locations | 1 site (Lille) |
| Trial ID | NCT05273138 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the heterogeneity of fibroblasts and immune cells in the skin of patients with systemic sclerosis (SSc). By analyzing blood samples and skin biopsies, the study seeks to understand the interactions between B lymphocytes and fibroblasts, which are crucial in the disease's pathophysiology. The research focuses on the molecular signatures of these cells to provide insights into the varying severity of SSc. This could lead to a better understanding of the disease and potential future therapeutic targets.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old diagnosed with systemic sclerosis according to ACR-EULAR 2013 criteria.
Not a fit: Patients with overlapping connective tissue diseases or those currently on immunosuppressive treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of systemic sclerosis and pave the way for more effective treatments.
How similar studies have performed: While the specific approach of analyzing fibroblast and immune cell interactions in SSc is novel, similar studies in other fibrosing diseases have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Man or woman over 18 years of age * With a systemic sclerosis meeting the ACR-EULAR 2013 criteria Having signed an informed consent * Being insured Exclusion Criteria: * Syndrome of overlap with another connective tissue disease according to the international diagnostic criteria * Immunosuppressive treatment within 12 months * Dosage of current corticosteroid therapy ≥10mg/d * Protected minors or adults * Pregnant or breastfeeding women * Deprived of their liberty * Persons in emergency situations * Persons who have refused or are unable to give informed consent
Where this trial is running
Lille
- Hop Claude Huriez Chu Lille — Lille, France (Recruiting)
Study contacts
- Principal investigator: David Launay, MD,PhD — University Hospital, Lille
- Study coordinator: David Launay, MD,PhD
- Email: david.launay@chru-lille.fr
- Phone: 0320445962
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.